Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
Key Highlights
- ➤KT-579 achieved ≥90% median IRF5 degradation across multiple dose levels in Phase 1
- ➤KT-579 suppressed inflammatory and interferon biomarkers by 88%-98% at Day 14
- ➤KT-579 lupus Phase 1b LUMORA trial planned to start by early 2027
- ➤KT-621 BROADEN2 AD trial completed; topline data expected by year-end 2026
- ➤Kymera held $1.6 billion cash and investments, with runway into 2029
Expert Statements
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics
“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology”
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics
“With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape.”
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics
“The last patient has now completed their week 16 visit in our KT-621 BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by year-end 2026.”
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics
“We also are planning to initiate our first Phase 3 AD trial by mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027.”
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics
“The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism.”
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics
“These findings exceed our expectations in terms of depth of degradation, safety and pathway suppression measured by downstream cytokines and gene transcripts.”
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics
“The results provide an important foundation as we advance KT-579, our 7(th) degrader to enter the clinic, toward a study in lupus patients and explore the opportunity for targeting IRF5 in additional autoimmune diseases.”
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics
“Beyond these clinical programs, our research engine remains focused on unlocking novel biology and pursuing high value targets to build the next wave of oral medicines for patients who need effective, safe and convenient treatment options.”
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile
KT-579 LUMORA Phase 1b trial in lupus patients planned to start by early 2027
Get started
Create a free account to read the full story.